发明名称 |
MAP3K8 AS A MARKER FOR SELECTING A PATIENT AFFECTED WITH AN OVARIAN CANCER FOR A TREATMENT WITH A MEK INHIBITOR |
摘要 |
The present invention relates to the use of MAP3K8 protein to predict clinical outcome of a patient affected with a cancer, in particular ovarian cancer, or to select a patient for a treatment comprising one MEK inhibitor. The invention further relates to a method for monitoring a patient affected with a high-MAP3K8 ovarian cancer (i.e. an ovarian cancer with a high expression and/or activity level of MAP3K8) to a treatment comprising at least one MEK inhibitor. The invention also further relates to a MEK inhibitor for use in the treatment of high-MAP3K8 ovarian cancer and kit that can be used in the methods of the invention. |
申请公布号 |
WO2016041932(A1) |
申请公布日期 |
2016.03.24 |
申请号 |
WO2015EP71040 |
申请日期 |
2015.09.15 |
申请人 |
INSTITUT CURIE;INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
发明人 |
MECHTA-GRIGORIOU, FATIMA;MIEULET, VIRGINIE |
分类号 |
G01N33/574 |
主分类号 |
G01N33/574 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|